Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence
Dr. Sandip Patel (UC San Diego, Moores Cancer Center) and Dr. Deborah Doroshow (Tisch Cancer Center, Icahn School of Medicine at Mount Sinai) take a practical look at how treatment selection and sequencing are evolving in advanced EGFR-mutated non-small cell lung cancer (NSCLC). The discussion covers frontline regimen selection between osimertinib monotherapy, FLAURA2, and MARIPOSA, including the role of clinical features, ctDNA, CNS metastases, TP53 co-mutation, and treatment burden. The experts review subcutaneous amivantamab and the COCOON regimen, sequential planning across lines, second-line options including COMPEL and MARIPOSA-2, the role of Dato-DXd and ADC toxicity management, MET-directed resistance, and key takeaways on precision diagnostics and treatment tolerability. Tailored for community and academic oncologists, BCOPs, and the multidisciplinary thoracic oncology team.
Advertisement
Optimizing Treatment Selection and Sequencing in Advanced EGFR-Mutated NSCLC: Balancing Efficacy, Toxicity, and Emerging Evidence
Dr. Sandip Patel (University of California San Diego, Moores Cancer Center) welcomes Dr. Deborah Doroshow (Mount Sinai) for a practical discussion on treatment selection and sequencing in advanced EGFR-mutated non-small cell lung cancer (NSCLC). Dr. Patel frames the conversation around how clinical features, molecular findings, CNS involvement, and real-world treatment burden shape both frontline and post-progression decisions, and how emerging data on resistance, re-biopsy, and antibody-drug conjugate (ADC) approaches are entering practice.
Dr. Patel asks how supportive care demands, quality of life, and financial and time toxicities shape shared decision-making in frontline EGFR-mutated non-small cell lung cancer (NSCLC), and whether subcutaneous amivantamab has changed his colleague's risk-benefit assessment. Dr. Doroshow argues quality of life, time, and financial toxicity cannot be separated from efficacy, because efficacy is determined in a trial vacuum while effectiveness depends on whether patients can actually receive and tolerate the medicine.
Dr. Patel asks how anticipated next-line options factor into upfront treatment choice, framing it as a chessboard where early moves determine what is available later. Dr. Doroshow says she tries to think one step at a time because she cannot see three moves ahead, given how many ways therapies can be mixed and matched.
Dr. Patel asks how the next step differs based on whether the patient received osimertinib monotherapy, FLAURA2, or MARIPOSA, and how progression pattern, CNS involvement, and re-biopsy guide decisions, including which patients should get stereotactic body radiation therapy (SBRT) and which need a histologic diagnosis to rule out small cell transformation.
Dr. Doroshow opens with a question on the role of antibody-drug conjugates (ADCs) in EGFR-mutated lung disease, asking what it would take for Dr. Patel to consider a first- or second-line datopotamab deruxtecan (Dato-DXd) plus osimertinib approach. Dr. Patel describes Dato-DXd as a TROP2-directed ADC with FDA approval in refractory EGFR-mutated non-small cell lung cancer (NSCLC). He uses it second line after FLAURA2 or MARIPOSA, and typically third line after osimertinib monotherapy followed by MARIPOSA-2 (chemotherapy plus amivantamab). He is interested in moving Dato-DXd earlier with osimertinib based on preliminary efficacy and CNS-protective signals, but flags ADC chemotherapy-like toxicities — stomatitis, low-rate interstitial lung disease, dry eye, cytopenias, and alopecia.
Dr. Doroshow asks how Dr. Patel weighs COMPEL (osimertinib continuation with chemotherapy; progression-free survival [PFS] 8.4 vs. 4.4 months) against MARIPOSA-2 (amivantamab plus chemotherapy; PFS 6.3 vs. 4.2 months) for patients progressing on frontline osimertinib, and whether a prolonged chemotherapy-free interval changes willingness to rechallenge with platinum.
Dr. Doroshow transitions to MET-directed resistance and invites Dr. Patel to lead. He describes MET amplification or overexpression as a resistance pathway in roughly 15% of EGFR-mutated metastatic non-small cell lung cancer (NSCLC) patients. Amivantamab-based regimens, which target both EGFR and MET, may reduce MET-driven resistance though not eliminate it. Testing must distinguish DNA-level events (MET amplification, by copy number) from protein-level overexpression (by immunohistochemistry [IHC]). Telisotuzumab vedotin (Teliso-V), a MET-directed antibody-drug conjugate (ADC) with a monomethyl auristatin E (MMAE) payload, is an option for 3+ MET protein overexpression in more than 25% of cells. For genomic MET amplification, small molecule combinations — savolitinib (a CNS-penetrant third-generation MET inhibitor with peripheral edema and hepatotoxicity), capmatinib, or tepotinib paired with osimertinib or lazertinib — are standard.
Dr. Doroshow steps back and asks Dr. Patel for the single most important insight or data point likely to change his clinical practice in the near term. Dr. Patel returns to a foundational message: precision therapy is impossible without a precision diagnosis. He stresses the importance of identifying not only canonical EGFR mutations (exon 19 deletions and L858R) but also distinguishing them from EGFR exon 20 insertions, where some agents are useful and others are not. Understanding the patient's full molecular landscape determines whether FLAURA2, MARIPOSA, or osimertinib monotherapy is most appropriate, and these upfront decisions have downstream consequences in later lines of treatment. None of those conversations can begin without comprehensive upfront molecular testing.
